延安必康(002411.SZ):就擬出售部分醫藥類資產與南華生物達成初步共識
格隆匯12月10日丨延安必康(002411.SZ)公佈,為逐步剝離醫藥業務,進一步完善和調整公司產業和投資結構,更加專注於發展新能源新材料產業,公司(“乙方”)於2021年12月10日與南華生物醫藥股份有限公司(“南華生物”或“甲方”)簽署《資產收購意向協議書》。 甲、乙雙方從各自聚焦主業,實現優勢資源整合、協同發展的考慮,經初步協商,就甲方擬收購乙方持有的部分醫藥類資產的相關事宜達成初步共識。
通過此次交易,公司擬逐步剝離醫藥業務,進一步完善和調整公司產業和投資結構,更加專注於發展新能源新材料產業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.